Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Gazyva Obinutuzumab Chronic Lymphocytic Leukemia Reimburse Complete Aug 11, 2014 Jan 27, 2015
Giotrif Afatinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse Complete Jun 7, 2013 May 2, 2014
Halaven Eribulin Mesylate Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete Feb 9, 2012 Aug 2, 2012
Ibrance Palbociclib Withdrawn Nov 11, 2015
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete Sep 28, 2018 May 3, 2019
Ibrance Resubmission Palbociclib Advanced breast cancer Reimburse with clinical criteria and/or conditions Complete Jun 10, 2016 Nov 21, 2016
Iclusig Ponatinib Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete Mar 13, 2015 Oct 1, 2015
Idhifa Enasidenib Acute myeloid leukemia (AML) Do not reimburse Complete Apr 5, 2019 Oct 31, 2019
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Reimburse with clinical criteria and/or conditions Complete Aug 15, 2014 Mar 5, 2015
Imbruvica Ibrutinib Waldenstrom's Macroglobulinemia Do not reimburse Complete Apr 21, 2016 Nov 3, 2016